Slide 1: BONESUPPORT Q1 (2025) Report
BONESUPPORT Q1 (2025) Report April 24th , 2025 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – First quarter report 2025
BONESUPPORT – First quarter report 2025 Q1 2025: • Net sales SEK 284 m, growth: +54% versus Q1 2024, (+50% in constant exchange rates, CER) • Adjusted Operating result (before effects of incentive programs): SEK 40 m (SEK 42 m), including negative impact of currency swings of 30 mSEK • Reported EBIT
Slide 4: Continued strong momentum for CERAMENT G in the US
Continued strong momentum for CERAMENT G in the US • CERAMENT G in the US reaching SEK 178 m in the quarter • Total antibiotic eluting CERAMENT for the Group grew with 72% versus Q1 2024 CBVF= CERAMENT Bone Void Filler CG = CERAMENT G (Gentamicin) CV = CERAMENT V (Vancomycin) 4 NA CBVF also contains
Slide 5: North America: Good pick up in Trauma for CERAMENT G
North America: Good pick up in Trauma for CERAMENT G Q1 2025 • Sales of SEK 231 m (SEK 141 m) Growth of 63% over Q1 2024 • Growth of 59% in constant exchange rate (CER) • Large swings in USD versus SEK • Announced tariffs Highlights in quarter: • CERAMENT G sales of SEK 178 m, growth of 92% • AAOS -
Slide 6: Sales CERAMENT G - USA, MUSD per quarter
18,0 16,0 14,0 12,0 10,0 8,0 6,0 4,0 2,0 0,0 Sales CERAMENT™ |G - USA ONESUPPORT MUSD per quarter 16,4 14,0 12,5 10,2 35 6,8 5,7 47 3,2 1,3 Q4-22 Qi-23 Q2-23 Q3-23 Q4-23 Qi-24 Q2-24 Q3-24 Q4-24 Qi-25
Slide 7: EUROW: Market share gains fuel sales performance
EUROW Market share gains fuel sales performance Q1 2025 • Sales of SEK 52 m, growth of 22% vs Q1 2024 • Growth of 21% in constant exchange rates (CER) and 10% sequential growth (Q1 2025 vs Q4 2024) • Lingering impact from UK NHS prioritization program Highlights • EUROW Booster • Market authorizatio
Slide 8: Financial Report
BONESUPPORT Q1 (2025) Report Financial Report 8
Slide 9: Net Sales, SEK million
Q1 2025 net sales SEK 283.5 m Revenue vs PY Increase Decrease Total • NA: 63 percent reported growth. 300,0 6,6 283,5 83,5 9,0 59 percent growth in CER 250,0 • EUROW: 22 percent reported growth. Net Sales, SEK million 21 percent growth CER 200,0 184,4 150,0 100,0 50,0 0,0 Org growth NA fx YTD 2024 O
Slide 10: Gross Margin: North America and EUROW net sales
North +63% (+59% CER) +22% (+21% CER) America Net sales Q1-25 EUROW Net sales Q1-25 North America 2025 2024 EUROW 2025 2024 SEK m Q1 Q4 Q3 Q2 Q1 SEK m Q1 Q4 Q3 Q2 Q1 Net Sales 231,2 209,4 192,0 173,0 141,5 Net Sales 52,3 47,6 45,5 46,8 43,0 Gross profit 219,7 199,5 181,9 165,7 134,8 Gross profit 43,
Slide 11: R&D investments and commercial initiatives impacting
R&D investments and commercial initiatives impacting Key Figures 2025 2024 2023 SEK m Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Selling expenses 73,0 71,2 65,5 67,6 59,7 59,6 53,5 55,0 Sales Commissions and fees 79,3 70,4 65,5 62,2 48,2 44,4 42,7 37,2 Research and Development expenses 23,8 21,8 19,7 20,3 14,2 17,6 12
Slide 12: Strong underlying performance
Strong underlying performance Key Figures 2025 2024 2023 SEK m Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Net Sales 283,5 257,0 237,5 219,8 184,4 172,7 158,2 140,4 Gross Margin (%) 92,6 92,6 92,9 92,3 92,6 91,8 92,1 91,3 Operating profit 29,6 64,2 41,0 28,7 32,3 -7,7 14,9 6,0 Adj. Operating profit (i) 39,7 77,9 48,3 3
Slide 13: A solid trend in Adj. Operating result excluding exchange gains and losses
A solid trend in Adj. Operating result excluding exchange gains and losses on operating assets and liabilities • Adj. Operating margin (before fx) reported on an all-time high, reaching 24,6%. 13 (i) Operating result reduced with incentive expenses according to IFRS2 and social charges for these pro
Slide 14: Estimated low impact from US tariffs
Estimated low impact from US tariffs • With the assumption of current 10% tariffs, gross margin would drop from 92,6 % to 91,8 % - a total financial impact of SEK 2,2 million in Q1 2025.
Slide 15: BONESUPPORT Q1 (2025) Report
BONESUPPORT Q1 (2025) Report • 54% sales growth (50% in CER) • Strong performance for CERAMENT G USA • Solid Operating Profit development (before exchange impact) • SEK 40 million improvement in cash position in the period Sales growth above 40% (in CER) for FY 2025 15